Should clinicians prescribe statins to patients with atherosclerotic cardiovascular disease (ASCVD) who are receiving maintenance dialysis? Current guidelines generally advise against routine use due to inconclusive evidence, yet a study published in The American Journal of Cardiology reports a potential benefit based on pooled data.

A meta-analysis of seven observational studies including 116,535 dialysis-dependent patients with ASCVD found that statin therapy reduced all-cause mortality (hazard ratio [HR] 0.94; 95% confidence interval [CI]: 0.89–0.98; p = 0.004) and major adverse cardiovascular events (MACE) (HR 0.89; 95% CI: 0.80–0.98; p = 0.02). The analysis did not show significant associations with cardiovascular mortality, myocardial infarction, or stroke.

These findings suggest that statins may offer survival and cardiovascular event–reduction benefits for this high-risk population, potentially challenging current recommendations. However, the evidence base consists solely of observational studies, and residual confounding cannot be excluded. Clinicians should balance possible benefits against the absence of definitive randomized controlled trial evidence before initiating therapy in this setting.